TY - JOUR
T1 - Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy
AU - Lu, Dai Yin
AU - Yalçin, Hulya
AU - Yalçin, Fatih
AU - Zhao, Min
AU - Sivalokanathan, Sanjay
AU - Valenta, Ines
AU - Tahari, Abdel
AU - Pomper, Martin G.
AU - Abraham, Theodore P.
AU - Schindler, Thomas H.
AU - Abraham, M. Roselle
N1 - Funding Information:
This work was supported by the JTB (John Taylor Babbit) Foundation, Chatham, New Jersey and startup funds from the UCSF Division of Cardiology to Dr. Abraham. Dr. Lu was supported by Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program, Taipei, Taiwan , no. 104-V-A-005 . Dr. Yalçin was supported by a Fulbright Fellowship (Bureau of Educational and Cultural Affairs, United States Department of State) .
Funding Information:
This work was supported by the JTB (John Taylor Babbit) Foundation, Chatham, New Jersey and startup funds from the UCSF Division of Cardiology to Dr. Abraham. Dr. Lu was supported by Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program, Taipei, Taiwan, no. 104-V-A-005. Dr. Yal?in was supported by a Fulbright Fellowship (Bureau of Educational and Cultural Affairs, United States Department of State).
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Patients with hypertrophic cardiomyopathy (HC) are at increased risk of sudden cardiac death. Abnormalities in myocardial blood flow (MBF) detected by positron emission tomography (PET) are common in HC, but a PET marker that identifies patients at risk of sudden cardiac death is lacking. We hypothesized that disparities in regional myocardial perfusion detected by PET would identify patients with HC at risk of ventricular arrhythmias. To test this hypothesis, we quantified global and regional MBFs by 13 NH 3 -PET at rest and at stress, and developed a heterogeneity index to assess MBF heterogeneity in 133 symptomatic patients with HC. The MBF heterogeneity index was computed by dividing the highest by the lowest regional MBF value, at rest and after vasodilator stress, in each patient. High stress MBF heterogeneity was defined as an index of ≧1.85. Patients with HC were stratified by the presence or the absence of ventricular arrhythmias, defined as sustained ventricular tachycardia (VT) and/or nonsustained VT, during follow-up. We found that global and regional MBFs at rest and stress were similar in patients with HC with or without ventricular arrhythmias. Variability in regional stress MBF was observed in both groups, but the stress MBF heterogeneity index was significantly higher in patients with HC who developed ventricular arrhythmias (1.82 ± 0.77 vs 1.49 ± 0.25, p <0.001). A stress MBF heterogeneity index of ≧1.85 was an independent predictor of both sustained VT (hazard ratio 16.1, 95% confidence interval 3.2 to 80.3) and all-VT (sustained-VT + nonsustained VT: hazard ratio 3.7, 95% confidence interval 1.4 to 9.7). High heterogeneity of stress MBF, reflected by an MBF heterogeneity index of ≥1.85, is a PET biomarker for ventricular arrhythmias in symptomatic patients with HC.
AB - Patients with hypertrophic cardiomyopathy (HC) are at increased risk of sudden cardiac death. Abnormalities in myocardial blood flow (MBF) detected by positron emission tomography (PET) are common in HC, but a PET marker that identifies patients at risk of sudden cardiac death is lacking. We hypothesized that disparities in regional myocardial perfusion detected by PET would identify patients with HC at risk of ventricular arrhythmias. To test this hypothesis, we quantified global and regional MBFs by 13 NH 3 -PET at rest and at stress, and developed a heterogeneity index to assess MBF heterogeneity in 133 symptomatic patients with HC. The MBF heterogeneity index was computed by dividing the highest by the lowest regional MBF value, at rest and after vasodilator stress, in each patient. High stress MBF heterogeneity was defined as an index of ≧1.85. Patients with HC were stratified by the presence or the absence of ventricular arrhythmias, defined as sustained ventricular tachycardia (VT) and/or nonsustained VT, during follow-up. We found that global and regional MBFs at rest and stress were similar in patients with HC with or without ventricular arrhythmias. Variability in regional stress MBF was observed in both groups, but the stress MBF heterogeneity index was significantly higher in patients with HC who developed ventricular arrhythmias (1.82 ± 0.77 vs 1.49 ± 0.25, p <0.001). A stress MBF heterogeneity index of ≧1.85 was an independent predictor of both sustained VT (hazard ratio 16.1, 95% confidence interval 3.2 to 80.3) and all-VT (sustained-VT + nonsustained VT: hazard ratio 3.7, 95% confidence interval 1.4 to 9.7). High heterogeneity of stress MBF, reflected by an MBF heterogeneity index of ≥1.85, is a PET biomarker for ventricular arrhythmias in symptomatic patients with HC.
UR - http://www.scopus.com/inward/record.url?scp=85045580262&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2018.01.022
DO - 10.1016/j.amjcard.2018.01.022
M3 - Article
C2 - 29678336
AN - SCOPUS:85045580262
SN - 0002-9149
VL - 121
SP - 1081
EP - 1089
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 9
ER -